



## New Diagnostics Working Group

### 2<sup>nd</sup> Expert Workshop on the development of tests for progression of latent tuberculosis infection (LTBI) to active disease

1<sup>st</sup> July 2016

Organized by the New Diagnostics Working Group  
Hosted by San Raffaele Hospital, Milan, Italy

#### Meeting room 2 A2

San Raffaele Telethon Institute for Gene Therapy  
Building DIBIT 1, 2<sup>nd</sup> floor  
Via Olgettina 58 – 20132 Milan

#### LIST OF PARTICIPANTS

(as of 30 June 2016)

##### NDWG LTBI Task Force

Alberto Matteelli, Coordinator  
University of Brescia  
Italy  
[alberto.matteelli@unibs.it](mailto:alberto.matteelli@unibs.it)

Susanna Capone  
University of Brescia  
Italy  
[susanna.capone@unibs.it](mailto:susanna.capone@unibs.it)

Gavin Churchyard  
Aurum Institute  
South Africa  
[GChurchyard@auruminstitute.org](mailto:GChurchyard@auruminstitute.org)

Daniela Cirillo, NDWG Co-Chair  
San Raffaele Research Institute  
Italy  
[cirillo.daniela@hsr.it](mailto:cirillo.daniela@hsr.it)

Frank Cobelens  
AIGHD and KNCV  
The Netherlands  
[f.cobelens@aighd.org](mailto:f.cobelens@aighd.org)

Christopher Gilpin  
WHO Global TB Programme

Switzerland  
[gilpinc@who.int](mailto:gilpinc@who.int)

Amita Gupta (*attending remotely*)  
Johns Hopkins School of Public Health  
USA  
[agupta25@jhmi.edu](mailto:agupta25@jhmi.edu)

Sandra Kik  
KNCV  
The Netherlands  
[Sandra.Kik@kncvtbc.org](mailto:Sandra.Kik@kncvtbc.org)

Molebogeng Rangaka (*attending remotely*)  
University College London  
UK  
[l.rangaka@ucl.ac.uk](mailto:l.rangaka@ucl.ac.uk)

Samuel Schumacher  
FIND  
Switzerland  
[Samuel.Schumacher@finddx.org](mailto:Samuel.Schumacher@finddx.org)

Alessandra Varga, NDWG Secretariat  
FIND  
Switzerland  
[alessandra.varga@finddx.org](mailto:alessandra.varga@finddx.org)

## **Experts**

Helen Ayles  
LSHTM / Zambart  
UK / Zambia  
[Helen@zambart.org.zm](mailto:Helen@zambart.org.zm)

Hanif Esmail  
Oxford University Hospital  
UK  
[hanifesmail@gmail.com](mailto:hanifesmail@gmail.com)

Delia Goletti  
National Institute for Infectious Diseases  
Italy  
[delia.goletti@inmi.it](mailto:delia.goletti@inmi.it)

David Lewinsohn (*attending remotely*)  
University of Oregon  
Chair, Working Group on New Vaccines

USA  
[lewinsod@ohsu.edu](mailto:lewinsod@ohsu.edu)

Christian Lienhardt  
WHO Global TB Programme  
Switzerland  
[lienhardtc@who.int](mailto:lienhardtc@who.int)

Anna Mandalakas  
Baylor College of Medicine  
USA  
[anna.mandalakas@bcm.edu](mailto:anna.mandalakas@bcm.edu)

Thomas Scriba (*attending remotely*)  
University of Cape Town  
South Africa  
[thomas.scriba@uct.ac.za](mailto:thomas.scriba@uct.ac.za)

## **Industry Representatives**

William Cruikshank  
Oxford Immunotec  
UK  
[wcrruikshank@oxfordimmunotec.com](mailto:wcrruikshank@oxfordimmunotec.com)

Ludwig Deml  
Lophius Biosciences GmbH  
Germany  
[ludwig.deml@lophius.com](mailto:ludwig.deml@lophius.com)

Paola Legnani  
QIAGEN

UK  
[Paola.Legnani@qiagen.com](mailto:Paola.Legnani@qiagen.com)

Oksana Markova  
Generium  
Russia  
[oamarkova@generium.ru](mailto:oamarkova@generium.ru)

Morten Ruhwald  
Statens Serum Institut  
Denmark  
[MORU@ssi.dk](mailto:MORU@ssi.dk)